A major challenge in the clinical trial space is ensuring a diverse group of patients enrolls in the program. | A major challenge in the clinical trial space is ensuring a diverse group of patients ...
More than three-quarters of lupus patients taking obinutuzumab (Gazvya) had a significant improvement in their symptoms after a year on the drug, researchers reported March 6 in The New England ...
Geroscience examines the underlying biology of aging to delay chronic diseases and extend the healthy years of human life.
Soo-Kyung and Jae Lee, whose daughter has FOXG1 syndrome, developed the gene therapy that could one day treat people with this severe disorder.
When Elise Felicione tried to design a clinical trial for a supplement, 5 things got in the way. It’s a lesson for the ...
Daiichi Sankyo announced that the first patient has been dosed in the global phase 3 TROPION-Lung17 trial. The study is evaluating DATROWAY in patients with locally advanced or metastatic nonsquamous ...
A Phase I/IIa clinical trials co-led by Linda Laux, MD, from Ann & Robert H. Lurie Children's Hospital of Chicago, show that ...
ClinCapture President and CEO Scott Weidley today announced a major expansion of artificial intelligence capabilities within the company's Captivate® platform, embedding AI directly into the ...
Kyowa Kirin announced it is discontinuing all ongoing clinical trials for rocatinlimab, an investigational anti-OX40 monoclonal antibody, after a safety review identified “emerging concerns” of ...
South Korea's Hyundai Bioscience said Friday it has joined a global clinical trial in Vietnam for dengue fever, a ...
In the UK, wide‑ranging reforms coming into force on 28 April 2026 are designed to streamline approvals, embed a more risk‑proportionate approach and place transparency obligations on a clear ...
The UK’s National Health Service (NHS) has been awarded £47.8m ($63.8m) from the National Institute for Health and Care Research (NIHR) to pay for equipment that will increase the NHS’s ability to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results